The legal library gives you easy access to the FTC’s case information and other official legal, policy, and guidance documents.
West Penn Multi-List, Inc., a corporation, In the Matter of
The Commission charged that West Penn Multi-List, operator of the only MLS service for the Pittsburgh metropolitan area, unreasonablay restricted access to its MLS services, which restrained competition. Specifically, West Penn’s MLS rules limited publication and marketing of the listing of sellers’ properties based solely on the terms of the seller’s listing contract with the real estate broker. The MLS provider limited MLS access to those brokers with a traditional full-time listing agreement with their seller, thus constraining the ability of brokers with non-traditional listing agreements to compete. To settle the charges, West Penn agreed to a consent order which prohibits West Penn from adopting or enforcing rules that (1) require brokers to comply with the MLS form contract and submit copies of their listing contracts to the MLS, and that (2) discourage brokers and home sellers from contracting for services for terms of less than a year.
Lamp Labeling Study Agency Information Collection Activities; Submission for OMB Review; Comment Request
NAD Referral of Advertising Claims for ProCede
Global Marketing Group, Inc., et al.
Opinion 09-1
Opinion 09-1
0902004 Informal Interpretation
Apparel Rules Agency Information Collection Activities; Submission for OMB Review; Comment Request
Concurring Statement of Commissioner Jon Leibowitz, FTC Staff Report: Self-Regulatory Principles for Online Behavioral Advertising
Concurring Statement of Commissioner Pamela Jones Harbour, FTC Staff Report: Self-Regulatory Principles for Online Behavioral Advertising
Alternatel, Inc., G.F.G. Enterprises LLC, also d/b/a Mystic Prepaid, Voice Prepaid, Inc., Telecom Express, Inc., Telexpress, Inc., Voice Distributors, Inc., et al.
Teva Pharmaceutical Industries Ltd., a corporation, and Barr Pharmaceuticals, Inc., a corporation, In the Matter of
In December 2008, the Commission settled antitrust concerns raised by the proposed $8.9 billion acquisition of Barr Pharmaceuticals by Teva Pharmaceutical Industries. The proposed acquisition would have lessened competition in the markets for 17 commonly used generic medications including drugs used in the treatment of cancer, bacterial infections, diabetes, acid reflux, and depression as well as several varieties of oral contraceptives. According to the Commission’s complaint, the acquisition would have likely led to higher prices for consumers through the removal of one of only four competitors in each of these markets. The Commission’s consent agreement requires both Teva and Barr to sell assets in 29 U.S. markets to either Watson Pharmaceuticals or Qualitest Pharmaceuticals.